Faculty Summaries
Igor Astsaturov, MD, PhD
Igor Astsaturov, MD, PhD
Assistant Professor
Office Phone: 215-214-4297
Lab Phone: 215-728-3971
Office: W462

Cancer Metabolism and signaling

  • The central role for sterol metabolism in regulation of cell growth and signaling.
  • Pancreatic cancer biology and "smart drugs" for treatment of pancreatic cancer.
  • Translating therapeutic concepts to the clinic using the platform of patient-derived avatar models and genetically engineered pancreatic cancer models.
Description of research projects
Selected Publications

Fox Chase Programs

    1. Gabitova L, Restifo D, Gorin A, Manocha K, Handorf E, Yang DH, Cai KQ, Klein-Szanto AJ, Cunningham D, Kratz LE, Herman GE, Golemis EA, Astsaturov I. Endogenous Sterol Metabolites Regulate Growth of EGFR/KRAS-Dependent Tumors via LXR. Cell Rep. 2015 Sep 22;12(11):1927-38. doi: 10.1016/j.celrep.2015.08.023. Epub 2015 Sep 3. PubMed PMID: 26344763; PubMed Central PMCID: PMC4581991.
    2. Beeharry N, Banina E, Hittle J, Skobeleva N, Khazak V, Deacon S, Andrake M, Egleston BL, Peterson JR, Astsaturov I, Yen TJ. Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints. Cell Cycle. 2014;13(14):2172-91. doi: 10.4161/cc.29214. Epub 2014 Jun 23. PubMed PMID: 24955955; PubMed Central PMCID: PMC4111673.
    3. Perkins J, Boland P, Cohen SJ, Olszanski AJ, Zhou Y, Engstrom P, Astsaturov I. Successful imatinib therapy for neuroendocrine carcinoma with activating Kit mutation: a case study. J Natl Compr Canc Netw. 2014 Jun;12(6):847-52. PubMed PMID: 24925195; PubMed Central PMCID: PMC4112647.
    4. Gabitova L, Gorin A, Astsaturov I. Molecular pathways: sterols and receptor signaling in cancer. Clin Cancer Res. 2014 Jan 1;20(1):28-34. doi: 10.1158/1078-0432.CCR-13-0122. Epub 2013 Oct 24. Review. PubMed PMID: 24158702;PubMed Central PMCID: PMC3859141.
    5. Liu H, Xiao F, Serebriiskii IG, O'Brien SW, Maglaty MA, Astsaturov I, Litwin S, Martin LP, Proia DA, Golemis EA, Connolly DC. Network analysis identifies an HSP90-central hub susceptible in ovarian cancer. Clin Cancer Res. 2013 Sep 15;19(18):5053-67. doi: 10.1158/1078-0432.CCR-13-1115. Epub 2013 Jul 30. PubMed PMID: 23900136; PubMed Central PMCID: PMC3778161.
    6. Bagnyukova TV, Restifo D, Beeharry N, Gabitova L, Li T, Serebriiskii IG, Golemis EA, Astsaturov I. DUSP6 regulates drug sensitivity by modulating DNA damage response. Br J Cancer. 2013 Aug 20;109(4):1063-71. doi: 10.1038/bjc.2013.353. Epub 2013 Jul 9. PubMed PMID: 23839489; PubMed Central PMCID: PMC3749559.
    7. Sukhanova A, Gorin A, Serebriiskii IG, Gabitova L, Zheng H, Restifo D, Egleston BL, Cunningham D, Bagnyukova T, Liu H, Nikonova A, Adams GP, Zhou Y,Yang DH, Mehra R, Burtness B, Cai KQ, Klein-Szanto A, Kratz LE, Kelley RI, Weiner LM, Herman GE, Golemis EA, Astsaturov I. Targeting C4-demethylating genes in the cholesterol pathway sensitizes cancer cells to EGF receptor inhibitors via increased EGF receptor degradation. Cancer Discov. 2013 Jan;3(1):96-111. doi:10.1158/2159-8290.CD-12-0031. Epub 2012 Nov 2. PubMed PMID: 23125191; PubMed Central PMCID: PMC3546138.
    8. Gorin A, Gabitova L, Astsaturov I. Regulation of cholesterol biosynthesis and cancer signaling. Curr Opin Pharmacol. 2012 Dec;12(6):710-6. doi: 10.1016/j.coph.2012.06.011. Epub 2012 Jul 21. Review. PubMed PMID: 22824431;PubMed Central PMCID: PMC3504641.
    9. Dotan E, Meropol NJ, Zhu F, Zambito F, Bove B, Cai KQ, Godwin AK, Golemis EA, Astsaturov I, Cohen SJ. Relationship of increased aurora kinase A gene copy number, prognosis and response to chemotherapy in patients with metastatic colorectal cancer. Br J Cancer. 2012 Feb 14;106(4):748-55. doi: 10.1038/bjc.2011.587. Epub 2012 Jan 12. PubMed PMID: 22240781; PubMed Central PMCID: PMC3322945.
    10. Bagnyukova TV, Serebriiskii IG, Zhou Y, Hopper-Borge EA, Golemis EA, Astsaturov I. Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents? Cancer Biol Ther. 2010 Nov 1;10(9):839-53. Epub 2010 Nov 1.Review. PubMed PMID: 20935499; PubMed Central PMCID: PMC3012138.
    11. Astsaturov I, Ratushny V, Sukhanova A, Einarson MB, Bagnyukova T, Zhou Y, Devarajan K, Silverman JS, Tikhmyanova N, Skobeleva N, Pecherskaya A, Nasto RE,Sharma C, Jablonski SA, Serebriiskii IG, Weiner LM, Golemis EA. Synthetic lethal screen of an EGFR-centered network to improve targeted therapies. Sci Signal.2010 Sep 21;3(140):ra67. doi: 10.1126/scisignal.2001083. PubMed PMID: 20858866;PubMed Central PMCID: PMC2950064.
    12. Astsaturov IA, Meropol NJ, Alpaugh RK, Burtness BA, Cheng JD, McLaughlin S, Rogatko A, Xu Z, Watson JC, Weiner LM, Cohen SJ. Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma. Am J Clin Oncol. 2011 Feb;34(1):70-5. doi: 10.1097/COC.0b013e3181d2734a. PubMed PMID: 20458210; PubMed Central PMCID: PMC3030655.
    13. Astsaturov I, Cohen RB, Harari PM. Clinical application of EGFR inhibitors in head and neck squamous cell cancer. Cancer Treat Res. 2008;139:135-52. Review.PubMed PMID: 18236715.
All publications